Staphylococcus aureus clumping factor A (ClfA) (ClfA)

Staphylococcus aureus clumping factor A (ClfA) and related fibrinogen-binding Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs), such as ClfB and Fibronectin-binding proteins (FnbpA/B), are critical surface proteins that mediate bacterial interaction with host extracellular matrix components (PubMed: 24595231). ClfA, the most extensively studied, binds to the C-terminus of the fibrinogen gamma-chain, facilitating bacterial attachment to blood clots and damaged endothelium (UniProt P0C0S6). These proteins are essential for the formation of bacterial clumps and biofilms, which protect S. aureus from host immune defenses and antibiotic penetration (PubMed: 19129341). In clinical settings, these MSCRAMMs are major drivers of invasive diseases such as infective endocarditis, bacteremia, and prosthetic joint infections (PubMed: 12618444). Therapeutic strategies targeting these molecules include monoclonal antibodies like tefibazumab and various vaccine candidates designed to disrupt adhesion and enhance opsonophagocytosis (PubMed: 15107134). Despite their importance in pathogenesis, clinical trials targeting these surface proteins have often failed to meet primary efficacy endpoints, suggesting a need for multi-target approaches (PubMed: 16963611).

Other names

Clumping factor AMSCRAMMsMicrobial Surface Components Recognizing Adhesive Matrix MoleculesFibrinogen-binding protein AClfA proteinClfBFnbpAFnbpB

Therapeutic agents target the ligand-binding domains (typically the A domain) of ClfA and related MSCRAMMs to competitively inhibit their binding to host fibrinogen, thereby preventing bacterial colonization, reducing platelet aggregation, and facilitating immune-mediated clearance (PubMed: 15107134, PubMed: 24595231).